Erythrocyte binding inhibition of PvTRAg38 by purified antibodies from the <i>P. vivax</i> patients’ sera.

<p>Values are mean ± standard deviation of three different experiments. The erythrocyte binding inhibition increased significantly after antibody purification (P<0.05).</p><p>Normal Healthy Sera at 1∶10 dilutions showed 4.1±2.3% erythrocyte binding inhibition.</p><p>Erythrocyte binding without antibody (only PBS) was considered as 100% binding.</p>*<p>Antibodies were affinity purified from the pooled <i>P.vivax</i> infected patient sera using CarboxyLink™ Immobilization Kit (Thermo scientific, Rockford, USA) according to manufacturer’s protocol. Briefly, 2 mg of PvTRAg38 was coupled to the resin, and after washing with PBS, bound antibody was eluted by 0.2 M glycine-HCl. The purified antibody was dialysed in 50 mM Tris-HCl and used in the erythrocyte binding inhibition assay.